Hikma Pharmaceuticals (HIK)

 

Latest News

Hikma appoints chief scientific officer and head of R&D

Hikma Pharmaceuticals has appointed Surendera Tyagi as group chief scientific officer and global head of research and d...

Hikma Appoints Dr. Surendera Tyagi

RNS Number: 8062B Hikma Pharmaceuticals Plc 15 January 2018 PRESS RELEASE Hikma Appoints Dr. Surendera Tyagi as Group Chief Scientific Officer and Global Head of R&D London, 15 January 2018 - Hikma Pharmaceuticals PLC (Hikma, Group) (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY) (rated Ba1 Moody's / BB+ S&P, both stable), today announc...

Broker Forecast - Jefferies International issues a broker note on Hikma Pharmaceuticals PLC

Jefferies International today downgrades its investment rating on Hikma Pharmaceuticals PLC (LON:HIK) to underperfor...

Total Voting Rights

RNS Number: 9826A Hikma Pharmaceuticals Plc 04 January 2018 Hikma Pharmaceuticals PLC Total Voting Rights and Capital LONDON, 4 January 2018 - In accordance with the UK Financial Conduct Authority's (the " FCA ") DTR 5.6.1, Hikma Pharmaceuticals PLC (LEI: 549300BNS685UXH4JI75) (LSE: HIK) (NasdaqDubai: HIK) notifies the market that as at 31 D...

All News

DateHeadlineSource
15-01-18Hikma appoints chief scientific officer and head of R&DStockMarketWire
15-01-18Hikma Appoints Dr. Surendera TyagiRNS
10-01-18Broker Forecast - Jefferies International issues a broker note on Hikma Pharmaceuticals PLCStockMarketWire
04-01-18Total Voting RightsRNS
19-12-17Hikma reaches licensing agreement with CelltrionRNS
13-12-17Hikma- Dihydroergotamine Mesylate Injection, USPRNS
12-12-17Holding(s) in CompanyRNS
11-12-17Holding(s) in CompanyRNS
04-12-17Broker Forecast - Jefferies International issues a broker note on Hikma Pharmaceuticals PLCStockMarketWire
01-12-17Total Voting RightsRNS
01-12-17Hikma Ventures investment in Prognos StockMarketWire
30-11-17Hikma Ventures- $20.5m Series C round for PrognosRNS
28-11-17AnnouncementRNS
27-11-17Hikma invests in BiolinqStockMarketWire
27-11-17Hikma Ventures invests in BiolinqRNS
22-11-17Holding(s) in CompanyRNS
20-11-17Holding(s) in CompanyRNS
14-11-17Broker Forecast - Peel Hunt issues a broker note on Hikma Pharmaceuticals PLCStockMarketWire
14-11-17Holding(s) in CompanyRNS
14-11-17Hikma Acquires Products from Boehringer IngelheimRNS
10-11-17Broker Forecast - JP Morgan Cazenove issues a broker note on Hikma Pharmaceuticals PLCStockMarketWire
10-11-17Broker Forecast - HSBC issues a broker note on Hikma Pharmaceuticals PLCStockMarketWire
09-11-17Time to buy bombed-out Hikma Pharmaceuticals?Interactive Investor
09-11-17Broker Forecast - Numis issues a broker note on Hikma Pharmaceuticals PLCStockMarketWire
09-11-17Broker Forecast - Stifel issues a broker note on Hikma Pharmaceuticals PLCStockMarketWire
09-11-17UK housing market setback weighs on FTSE StockMarketWire
09-11-17Hikma maintains revenues forecastsStockMarketWire
09-11-17Trading StatementRNS
08-11-17Holding(s) in CompanyRNS
03-11-17Hikma US unit launches generic equivalents to AncobonStockMarketWire
03-11-17Hikma launches Flucytosine Capsules USP in USRNS
02-11-17Holding(s) in CompanyRNS
01-11-17Total Voting RightsRNS
30-10-17Hikma US unit launches Pantoprazole sodium for injectionStockMarketWire
30-10-17Hikma launches Pantoprazole Sodium for InjectionRNS
06-10-17Broker Forecast - JP Morgan Cazenove issues a broker note on Hikma Pharmaceuticals PLCStockMarketWire
05-10-17Block listing Interim ReviewRNS
02-10-17Total Voting RightsRNS
28-09-17Holding(s) in CompanyRNS
25-09-17Holding(s) in CompanyRNS

RSS feeds

  • Editorial news feed for LSE:HIK Editorial
  • Regulatory news feed for LSE:HIK Regulatory

Join interactive investor

  • £22.50 fixed quarterly charge includes £22.50 in trading credits
  • £10 per trade or £6 for frequent traders
  • No % platform fees
  • £1 per trade for regular investment or dividend reinvestment

Open an account